Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors
Tusamitamab ravtansine demonstrated a tolerable safety profile at a dose of 80-170 mg/m<sup>2</sup> in three different administration schedules in Japanese adults with metastatic solid tumors.
Authors
- Nathalie Fagniez (ORCID: https://orcid.org/0009-0006-7381-8657)
- Keisuke Tada (ORCID: https://orcid.org/0000-0003-3051-5841)
- Shinobu Ohshima
- Saori Mishima
- Kentaro Yamazaki (ORCID: https://orcid.org/0000-0001-6269-9345)
- Shigenori Kadowaki (ORCID: https://orcid.org/0000-0001-9923-5309)
- Takayuki Yoshino (ORCID: https://orcid.org/0000-0002-0489-4756)
- Kei Muro (ORCID: https://orcid.org/0000-0002-5572-743X)
- Tomoyuki Tanaka
- Takeshi Kawakami
Institutions
- Sanofi (France) (FR)
- Shizuoka Cancer Center (JP)
- Aichi Cancer Center (JP)
- Sanofi (Japan) (JP)
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-05-25
- DOI
- https://doi.org/10.1007/s10147-025-02784-4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi